Private labelling and packaging: To come to our company, you can get end-to-end assistance from logo and brand design and label compliance (FSSAI/US FDA)
That being said, current research has been focused on the ability of the peptide to reduce body weight as well as the identifying the optimal dose-response relationship between treatment with cagrilintide and overall body weight [1]
In April 2026, the FDA listed BPC-157-related and TB-500-related bulk drug substances for Pharmacy Compounding Advisory Committee discussion on July 23, 2026, regarding possible inclusion on the 503A Bulks List
The University Hospitals Cleveland Study analyzed 286,000 patient records, finding a 52% increased risk of gastroparesis in patients taking GLP-1 medications
Ingredients with strong evidence and low irritation risk are the best starting point: glutathione, tranexamic acid, azelaic acid, niacinamide, and kojic acid